12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tedizolid phosphate: Phase III completed enrollment

Trius completed enrollment of 658 patients in the in the double-blind, international Phase III ESTABLISH 2 trial evaluating IV 200 mg tedizolid followed by oral tedizolid both once daily for 6 days and placebo for 4 days vs. 600 mg IV linezolid followed by oral linezolid both twice daily for 10 days. Patients will receive at least 2 IV doses and may receive IV therapy for the entire treatment....

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >